MA-DEME-OFFSHORE-US
5.11.2021 07:02:12 CET | Business Wire | Press release
DEME Offshore US LLC (“DEME Offshore” or “the Company”), the world’s leading offshore wind farm contractor, today announced that it has secured a +$1.1 Billion Balance of Plant (BoP) contract for the construction of the Coastal Virginia Offshore Wind (CVOW) project in a Consortium with Prysmian. The contract, with a total value amounting to +$1.9 Billion, has been awarded by Dominion Energy Virginia, a subsidiary of Dominion Energy Inc., to a consortium made up of DEME Group and Prysmian.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104006432/en/
The agreement is the largest offshore wind installation contract ever awarded in the U.S. Upon expected completion in 2026, the CVOW will be the largest wind farm in the U.S., and one of the largest in the world.
The CVOW project will play a crucial role in helping the Commonwealth of Virginia meet its goal of becoming carbon neutral by 2045. The project is located at approximately 27 miles (43 km) off the coast of Virginia Beach, VA, US. The 2.6GW offshore wind farm will be capable of supplying clean energy to as many as 660,000 households, while reducing carbon emissions by over 2 million tons per year.
DEME Offshore’s CVOW BoP contract includes the transport and installation of 176 monopile transition piece foundations, three offshore substations, scour protection and the supply and installation of export and inter-array submarine cable systems. DEME Offshore will oversee the complete offshore installation works for the foundations, substations, infield cables, as well as part of the export cables. For the fulfilment of the project, DEME Offshore entered in a consortium with Prysmian, the world leader in underwater energy cable systems.
“DEME Offshore brings valuable industry knowledge and years of experience to our Coastal Virginia Offshore Wind project ,” says Joshua Bennett, Dominion Energy vice president of offshore wind . “We look forward to working with DEME Offshore to advance offshore wind off the coast of Virginia as we lead the Commonwealth’s clean-energy transition .”
Luc Vandenbulcke, CEO, DEME Group comments: “We are extremely proud to be playing such a significant role in this dynamic and growing U.S. market and seeing our efforts bring clean energy to American households. Following the award of the Vineyard offshore wind project installation works for foundations, substation and wind turbines and South Fork cable installation works, this partnership with Dominion Energy is an endorsement of our expertise and track record in enabling the energy transition process in the U.S. This contract further reaffirms DEME’s position as the pre-eminent contractor in the offshore wind installation industry both in the U.S. and globally.”
“We are grateful for Dominion Energy for the opportunity to launch this consortium. By working closely with our partners at Prysmian Powerlink, we will jointly support the project during the design and preparation phase with our joint expertise, and ultimately deliver on the promise of offshore wind power to the benefit of Virginia residents, businesses, and families,” said Jan Klaassen, Director, DEME Offshore US LLC.
Sid Florey, President, DEME Offshore US , commented: “This significant contract will allow us to further build out our US footprint, working with key partners and the local supply chain to grow jobs. We are pleased to continue supporting the growth of the U.S. offshore wind industry and demonstrating DEME’s commitment to this growing market.”
DEME Group has spent many years building up its presence in the U.S. market and established DEME Offshore US LLC in Boston in 2019. Today’s CVOW announcement is a fast follow on from earlier contract awards for Vineyard Wind 1 off the coast of Massachusetts, the first utility-scale offshore wind project in the U.S., and the South Fork offshore wind farm off the coast of Long Island. Upon expected completion in 2023, these projects will generate clean, renewable, affordable energy for over 400,000 homes and businesses in Massachusetts and over 70,000 homes on Long Island, while reducing carbon emissions by 1.6 million tons per year and 300,000 tons per year, respectively.
About DEME Offshore US LLC
DEME Offshore US LLC is a US company based in Boston, Massachusetts. DEME Offshore US LLC will source the installation vessel and experts from DEME Offshore, a member of the DEME Group. DEME Group, a world leader in the specialized fields of dredging, solutions for the offshore energy industry, infra marine and environmental works. The company can build on more than 140 years of know-how and is a front runner in innovation and new technologies. DEME’s vision is to work towards a sustainable future by offering solutions for global challenges: a rising sea level, a growing population, reduction of CO2 emissions, polluted rivers and soils and the scarcity of natural resources. DEME can rely on 5,200 highly skilled professionals and a modern fleet of over 100 vessels.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom